Santaris begins trials on the world's first microRNA treatment
Danish biopharmaceutical company Santaris Pharma has commenced a Phase I study on the world's first microRNA targeted medicine, for the treatment of hepatitis C.
The placebo-controlled, double-blind, randomized, single dose, dose-escalating safety study in 48 healthy male volunteers has already completed satisfactory treatment of the first cohort. If successful, Phase II studies in hepatitis C patients are scheduled for 2009.
SPC3649 (LNA-antimiR-122) targets microRNA-122, a small, liver-expressed, regulatory ribonucleic acid that has recently been shown to facilitate human hepatitis C replication in liver cells. The drug is also known to enhance the metabolism of cholesterol and fats.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze